$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000128581915000003 Filed on March 16, 2015

Income Statement

Concept	2015 Q1	2014	2013 Q4
Revenue	$388.0K	$539.0K	$169.0K
YoY Change	288.0%	-66.31%	-89.32%
Cost Of Revenue	$11.00K	$0.00
YoY Change
Gross Profit	$377.0K	$539.0K
YoY Change	277.0%	-66.31%
Gross Profit Margin	97.16%	100.0%
Selling, General & Admin	$8.990M	$22.60M	$3.890M
YoY Change	138.46%	43.04%	4.57%
% of Gross Profit	2384.62%	4192.95%
Research & Development	$9.318M	$47.95M	$10.19M
YoY Change	-22.46%	32.09%	8.98%
% of Gross Profit	2471.62%	8895.36%
Depreciation & Amortization	$60.00K	$326.0K	$80.00K
YoY Change	-25.0%	7.95%	-11.11%
% of Gross Profit	15.92%	60.48%
Operating Expenses	$18.32M	$70.55M	$14.07M
YoY Change	16.05%	35.37%	54.35%
Operating Profit	-$17.93M	-$70.01M	-$13.90M
YoY Change	14.32%	38.59%	84.55%
Interest Expense	$957.0K	$3.470M	-$600.0K
YoY Change	42.41%	46.66%	66.67%
% of Operating Profit
Other Income/Expense, Net	$218.0K	-$207.0K	$150.0K
YoY Change	-176.22%	-136.06%	-6.25%
Pretax Income	-$18.67M	-$73.70M	-$1.850M
YoY Change	12.2%	85.18%	-76.07%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$18.67M	-$73.67M	-$1.845M
YoY Change	12.18%	85.13%	-76.14%
Net Earnings / Revenue	-4811.6%	-13668.46%	-1091.72%
Basic Earnings Per Share
Diluted Earnings Per Share	-$511.8K	-$2.220M	-$61.08K
COMMON SHARES
Basic Shares Outstanding	37.80M shares		30.32M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.10M	$6.900M	$14.10M
YoY Change	34.29%	-51.06%	-37.05%
Cash & Equivalents	$1.441M	$400.0K	$1.384M
Short-Term Investments	$68.60M	$6.500M	$12.70M
Other Short-Term Assets	$116.0K	$1.200M	$86.00K
YoY Change	-18.88%	200.0%	-78.5%
Inventory	$566.0K	$600.0K	$0.00
Prepaid Expenses	$1.784M		$251.0K
Receivables	$500.0K	$300.0K	$400.0K
Other Receivables	$0.00	$100.0K	$71.00K
Total Short-Term Assets	$73.07M	$9.000M	$14.82M
YoY Change	34.98%	-39.19%	-40.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$727.0K	$800.0K	$939.0K
YoY Change	-26.49%	-11.11%	-9.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$439.0K	$1.000M	$100.0K
YoY Change	64.42%	25.0%	-37.11%
Total Long-Term Assets	$1.845M	$1.800M	$1.718M
YoY Change	-4.65%	5.88%	-8.37%
TOTAL ASSETS
Total Short-Term Assets	$73.07M	$9.000M	$14.82M
Total Long-Term Assets	$1.845M	$1.800M	$1.718M
Total Assets	$74.91M	$10.80M	$16.54M
YoY Change	33.61%	-34.55%	-37.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.611M	$4.900M	$2.329M
YoY Change	-6.39%	113.04%	-11.51%
Accrued Expenses	$6.438M	$7.100M	$3.944M
YoY Change	21.33%	82.05%	-17.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.019M	$6.300M	$5.600M
YoY Change		12.5%
Total Short-Term Liabilities	$20.07M	$18.30M	$11.87M
YoY Change	96.13%	53.78%	42.04%
LONG-TERM LIABILITIES
Long-Term Debt	$23.91M	$26.10M	$14.90M
YoY Change	-25.79%	75.17%	-25.89%
Other Long-Term Liabilities	$9.100M	$9.100M	$8.100M
YoY Change	8.33%	12.35%	76.09%
Total Long-Term Liabilities	$23.91M	$35.20M	$14.90M
YoY Change	-25.79%	53.04%	-25.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.07M	$18.30M	$11.87M
Total Long-Term Liabilities	$23.91M	$35.20M	$14.90M
Total Liabilities	$43.97M	$53.50M	$26.77M
YoY Change	3.6%	53.3%	-5.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$346.7M		-$254.4M
YoY Change	27.93%		18.55%
Common Stock	$378.0K		$304.0K
YoY Change	11.5%		17.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.85M	-$42.70M	-$18.38M
YoY Change
Total Liabilities & Shareholders Equity	$74.91M	$10.80M	$16.54M
YoY Change	33.61%	-34.55%	-37.78%

Cashflow Statement

Concept	2015 Q1	2014	2013 Q4
OPERATING ACTIVITIES
Net Income	-$18.67M	-$73.67M	-$1.845M
YoY Change	12.18%	85.13%	-76.14%
Depreciation, Depletion And Amortization	$60.00K	$326.0K	$80.00K
YoY Change	-25.0%	7.95%	-11.11%
Cash From Operating Activities	-$17.48M	-$58.04M	-$300.0K
YoY Change	56.89%	95.47%	-97.65%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$28.00K	-$60.00K
YoY Change	-100.0%	-86.27%	-85.0%
Acquisitions
YoY Change
Other Investing Activities	-$62.09M	$6.190M	-$4.870M
YoY Change	59.57%	-23.67%	-155.78%
Cash From Investing Activities	-$62.09M	$6.157M	-$4.940M
YoY Change	59.57%	-22.15%	-159.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$79.10M	$37.75M
YoY Change	109.26%	79.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$80.65M	$50.86M	5.470M
YoY Change	63.82%	134.91%	11.41%
NET CHANGE
Cash From Operating Activities	-$17.48M	-$58.04M	-300.0K
Cash From Investing Activities	-$62.09M	$6.157M	-4.940M
Cash From Financing Activities	$80.65M	$50.86M	5.470M
Net Change In Cash	$1.087M	-$1.030M	230.0K
YoY Change	-233.05%	657.35%	-50.0%
FREE CASH FLOW
Cash From Operating Activities	-$17.48M	-$58.04M	-$300.0K
Capital Expenditures	$0.00	$28.00K	-$60.00K
Free Cash Flow	-$17.48M	-$58.07M	-$240.0K
YoY Change	56.81%	94.23%	-98.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37802462	shares
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	550709113	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
CY2014	dei	Trading Symbol TradingSymbol	OMER
CY2013Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	596000	USD
CY2014Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	828000	USD
CY2013Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	858000	USD
CY2014Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	1280000	USD
CY2014	omer	Beginning Year Of Expiry For Net Operating Loss Carryforwards BeginningYearOfExpiryForNetOperatingLossCarryforwards	2019
CY2014Q4	omer	Classof Warrantor Right Exercise Priceof Warrantsor Rights Weighted Average Price ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice	25.06
CY2014	omer	Classof Warrantor Right Exercised During Period ClassofWarrantorRightExercisedDuringPeriod	57581	shares
CY2013Q4	omer	Computer Equipment Gross ComputerEquipmentGross	431000	USD
CY2014Q4	omer	Computer Equipment Gross ComputerEquipmentGross	403000	USD
CY2013Q4	omer	Deferred Tax Assets Tax Credit Carryforwards Research And Development DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment	5700000	USD
CY2014Q4	omer	Deferred Tax Assets Tax Credit Carryforwards Research And Development DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment	9600000	USD
CY2014Q4	omer	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2012Q4	omer	Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit	1100000	USD
CY2013Q4	omer	Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit	1100000	USD
CY2012	omer	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.02
CY2013	omer	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.03
CY2014	omer	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.02
CY2014	omer	Ending Year Of Expiry For Net Operating Loss Carryforwards EndingYearOfExpiryForNetOperatingLossCarryforwards	2034
CY2012Q1	omer	Lease Agreement Expense Incurred To Date Reimbursable By Landlord LeaseAgreementExpenseIncurredToDateReimbursableByLandlord	3000000	USD
CY2014	omer	Lease Extension Period LeaseExtensionPeriod	P5Y
CY2014	omer	Lease Term LeaseTerm	P15Y
CY2014Q4	omer	Long Term Debt Maturities Total Principal Payments LongTermDebtMaturitiesTotalPrincipalPayments	32185000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due NetOperatingLeasesFutureMinimumPaymentsDue	56851000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due Current NetOperatingLeasesFutureMinimumPaymentsDueCurrent	3364000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due In Five Years NetOperatingLeasesFutureMinimumPaymentsDueInFiveYears	4350000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due In Four Years NetOperatingLeasesFutureMinimumPaymentsDueInFourYears	4253000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due In Three Years NetOperatingLeasesFutureMinimumPaymentsDueInThreeYears	3686000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due In Two Years NetOperatingLeasesFutureMinimumPaymentsDueInTwoYears	3485000	USD
CY2014Q4	omer	Net Operating Leases Future Minimum Payments Due Thereafter NetOperatingLeasesFutureMinimumPaymentsDueThereafter	37713000	USD
CY2014	omer	Operating Lease Number Of Additional Renewal Option OperatingLeaseNumberOfAdditionalRenewalOption	2	lease_extension
CY2012	omer	Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding	67000	USD
CY2013	omer	Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding	0	USD
CY2014	omer	Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding	80000	USD
CY2013Q4	omer	Sales Agreement Average Share Price SalesAgreementAverageSharePrice	13.29
CY2013Q4	omer	Sales Agreement Net Proceeds SalesAgreementNetProceeds	4900000	USD
CY2013	omer	Sales Agreement Net Proceeds SalesAgreementNetProceeds	4868000	USD
CY2014	omer	Sales Agreement Net Proceeds SalesAgreementNetProceeds	68000	USD
CY2013Q4	omer	Sales Agreement Numberof Shares Sold During Period SalesAgreementNumberofSharesSoldDuringPeriod	374000	shares
CY2014	omer	Sales Agreement Termination Period SalesAgreementTerminationPeriod	2014-04-01
CY2014Q4	omer	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	3198388	shares
CY2014	omer	Warrant Expiration Date WarrantExpirationDate	2015-03-29
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2329000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4915000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3944000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7070000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	649000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1952000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2091000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2228000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	235685000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	285050000	USD
CY2012	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	511000	USD
CY2013	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	41000	USD
CY2014	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	863000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4281000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6252000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8918000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	511000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	41000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	863000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5878369	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7578319	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8915904	shares
CY2013Q4	us-gaap	Assets Assets	16535000	USD
CY2014Q4	us-gaap	Assets Assets	11090000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	14817000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	9157000	USD
CY2013Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	12717000	USD
CY2014Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	6532000	USD
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	231000	USD
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	230000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	43000	USD
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	30000	USD
CY2013	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	200000	USD
CY2013Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	231000	USD
CY2014Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	230000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	99000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	185000	USD
CY2013Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	145000	USD
CY2014Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	52000	USD
CY2013Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	127000	USD
CY2014Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	126000	USD
CY2013Q4	us-gaap	Cash Cash	1200000	USD
CY2014Q4	us-gaap	Cash Cash	354000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4005000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1520000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1384000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	354000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2485000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-136000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	68942000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	88399000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1866000	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	551435	shares
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1030000	USD
CY2014Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	6900000	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.25
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.25
CY2013Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	197000	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	139897	shares
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9154740	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30359508	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34185464	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30359508	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34185464	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	304000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	342000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38444000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39796000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73673000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8148000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9050000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	82822000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	108640000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2084000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3537000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5511000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	2770000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	3077000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	82822000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	108640000	USD
CY2012	us-gaap	Depreciation Depreciation	320000	USD
CY2013	us-gaap	Depreciation Depreciation	302000	USD
CY2014	us-gaap	Depreciation Depreciation	326000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	320000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	302000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	326000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.39
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.22
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.35
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.36
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.35
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.03
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.00
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.05
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.04
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1346000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2421000	USD
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18300000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M14D
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-511000	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-863000	USD
CY2013Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	615000	USD
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	615000	USD
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	9000	USD
CY2012	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2013	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	12500000	USD
CY2014	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10985000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15819000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22601000	USD
CY2013Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	308000	USD
CY2014Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	324000	USD
CY2014Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	4800000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1169000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5459000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4718000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-970000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	568000	USD
CY2012	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	4644000	USD
CY2013	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	3504000	USD
CY2014	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	902000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	438000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-84000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	987000	USD
CY2012	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1059000	USD
CY2013	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1555000	USD
CY2014	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	13000	USD
CY2012	us-gaap	Interest Expense InterestExpense	1729000	USD
CY2013	us-gaap	Interest Expense InterestExpense	2366000	USD
CY2014	us-gaap	Interest Expense InterestExpense	3470000	USD
CY2012	us-gaap	Interest Paid InterestPaid	1502000	USD
CY2013	us-gaap	Interest Paid InterestPaid	1709000	USD
CY2014	us-gaap	Interest Paid InterestPaid	2674000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	568000	USD
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	40000	USD
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	12000	USD
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	12000	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	64000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	71000	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	289000	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2900000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4300000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4500000	USD
CY2012Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2012-11-01
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16535000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11090000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11873000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18431000	USD
CY2012Q4	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	3950000	USD
CY2013Q4	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	12500000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5600000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	6446000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	7234000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	1000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	3064000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	11447000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	10439000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14898000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26263000	USD
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1626000	USD
CY2014Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1636000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32973000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21650000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50857000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-907000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7909000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6157000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34551000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29695000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58044000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-38444000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-10489000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-13592000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-13870000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1845000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-39796000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-16642000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-17991000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-18327000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-20713000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-73673000	USD
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2012	us-gaap	Operating Expenses OperatingExpenses	42907000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	11115000	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	14071000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	52116000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	15784000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	17262000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	17346000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	13300000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	13630000	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	20155000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	70547000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-36885000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10020000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13160000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13434000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-13902000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-50516000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15684000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17217000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17132000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-19975000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-70008000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	58563000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3995000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	1712000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4350000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4253000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4167000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4085000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	37713000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	631000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	0	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	0	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	481000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	600000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Thereafter OperatingLeasesFutureMinimumPaymentsReceivableThereafter	0	USD
CY2012	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	635000	USD
CY2013	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	550000	USD
CY2014	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	568000	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	205900000	USD
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	264100000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	495000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	589000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	86000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	120000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	472000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	130000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	574000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-207000	USD
CY2013Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	71000	USD
CY2014Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	68000	USD
CY2012	us-gaap	Paid In Kind Interest PaidInKindInterest	354000	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	502000	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	738000	USD
CY2012Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2200000	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	39000	USD
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2500000	USD
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	49547000	USD
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	47182000	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	58849000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	642000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	204000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	251000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1191000	USD
CY2012Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32300000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16100000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37800000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32306000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20988000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37754000	USD
CY2012	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	6492000	USD
CY2013	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	12699000	USD
CY2012	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	49282000	USD
CY2013	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	55295000	USD
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	65034000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	369000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	662000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1868000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	68857	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3030000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3010000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	939000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	782000	USD
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	379000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	392000	USD
CY2012	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6194000	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1464000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31922000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36297000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47946000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	679000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	679000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-254373000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328046000	USD
CY2012	us-gaap	Revenues Revenues	6022000	USD
CY2013Q1	us-gaap	Revenues Revenues	1095000	USD
CY2013Q2	us-gaap	Revenues Revenues	140000	USD
CY2013Q3	us-gaap	Revenues Revenues	196000	USD
CY2013Q4	us-gaap	Revenues Revenues	169000	USD
CY2013	us-gaap	Revenues Revenues	1600000	USD
CY2014Q1	us-gaap	Revenues Revenues	100000	USD
CY2014Q2	us-gaap	Revenues Revenues	45000	USD
CY2014Q3	us-gaap	Revenues Revenues	214000	USD
CY2014Q4	us-gaap	Revenues Revenues	180000	USD
CY2014	us-gaap	Revenues Revenues	539000	USD
CY2014Q4	us-gaap	Security Deposit SecurityDeposit	679000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	4281000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	6252000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	8918000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.86
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.88
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0095
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0166
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5166081	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.63
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	578000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2900000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	313381	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.30
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2005850	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.35
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.87
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.39
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	144348000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6969303	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8364469	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.38
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.52
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	139877000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8047969	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.40
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.06
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.72
CY2012	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	28000	shares
CY2013	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	40000	shares
CY2014	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	86500	shares
CY2014Q1	us-gaap	Share Price SharePrice	11.50
CY2012Q3	us-gaap	Share Price SharePrice	10.25
CY2013Q2	us-gaap	Share Price SharePrice	4.14
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M3D
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	98949000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M8D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M26D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y10M27D
CY2012Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3400000	shares
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3900000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3500000	shares
CY2014	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	28653	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	297303	shares
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32306000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16120000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37754000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	369000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	662000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1800000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-5554000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-6531000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-18384000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-42654000	USD
CY2013Q4	us-gaap	Tax Credit Carryforward Deferred Tax Asset TaxCreditCarryforwardDeferredTaxAsset	5707000	USD
CY2014Q4	us-gaap	Tax Credit Carryforward Deferred Tax Asset TaxCreditCarryforwardDeferredTaxAsset	9569000	USD
CY2013	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2014	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	212000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	212000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	212000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13600000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14500000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25800000	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24155690	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28560360	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33234294	shares
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our marketed drug product Omidria</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> (phenylephrine and ketorolac injection) 1%/0.3% is approved in the U.S. for use during cataract surgery or intraocular lens replacement (IOL replacement surgery) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from our proprietary PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> platform, which is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures, and is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omidria was approved by the U.S. Food and Drug Administration (FDA) in May 2014 for use during cataract surgery or IOL replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In October 2014 we were granted transitional pass-through reimbursement status from the Centers for Medicare and Medicaid Services (CMS) for Omidria, effective January 1, 2015. Pass-through status allows for separate payment under Medicare Part B for new drugs and other medical technologies that meet specific criteria. We commenced a controlled launch of Omidria to a small number of surgeons in the U.S. in February 2015, with the broad U.S. launch of the product anticipated in early April 2015.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Omidria for use in patients undergoing IOL replacement surgery. In the EU and other international territories, we plan to enter into one or more partnerships for the marketing and distribution of Omidria. Assuming approval of our MAA for Omidria and success in partnering for Omidria in Europe, we anticipate the initiation of EU marketing and sales of Omidria in 2015.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have six clinical-stage development programs in our pipeline, which also includes a diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies. For Omidria and each of our product candidates and our programs, we have retained all manufacturing, marketing and distribution rights.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001285819-15-000003-index-headers.html	Edgar Link	pending
0001285819-15-000003-index.html	Edgar Link	pending
0001285819-15-000003.txt	Edgar Link	pending
0001285819-15-000003-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
omer-20141231.xml	Edgar Link	completed
omer-20141231.xsd	Edgar Link	pending
omer-20141231x10k.htm	Edgar Link	pending
omer-20141231_cal.xml	Edgar Link	unprocessable
omer-20141231_def.xml	Edgar Link	unprocessable
omer-20141231_lab.xml	Edgar Link	unprocessable
omer-20141231_pre.xml	Edgar Link	unprocessable
omer-201412_chartx20416.jpg	Edgar Link	pending
omer-ex1024_leicester8th9t.htm	Edgar Link	pending
omer-ex1040_oxfordxomerosx.htm	Edgar Link	pending
omer-ex1045_inventivsecond.htm	Edgar Link	pending
omer-ex1046_hospiracommsup.htm	Edgar Link	pending
omer-ex121_ratioofearnings.htm	Edgar Link	pending
omer-ex231_consentofindepe.htm	Edgar Link	pending
omer-ex311_20141231.htm	Edgar Link	pending
omer-ex312_20141231.htm	Edgar Link	pending
omer-ex321_20141231.htm	Edgar Link	pending
omer-ex322_20141231.htm	Edgar Link	pending
omer-ex991_descriptionofca.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2015 Q1 Form 10-K Financial Statement

#000128581915000003 Filed on March 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2015 Q1 Form 10-K Financial Statement

#000128581915000003 Filed on March 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer